SASKATOON, Saskatchewan–(BUSINESS WIRE)– #Phase2–ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, announced today it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin® softgel capsules in patients with advanced cancer and m
Source link
